Effects of tetracycline on the pharmacokinetics of halofantrine in healthy volunteers

British Journal of Clinical Pharmacology

Volumn 58, Issue 1, 2004, Pages 52-55

  Bassi, Peter U ^a   Onyeji, Cyprian O ^b   Ukponmwan, Otas E ^b  

^a UNIVERSITY OF MAIDUGURI   (Nigeria)

^b OBAFEMI AWOLOWO UNIVERSITY   (Nigeria)

Author keywords

Halofantrine; Interaction; Pharmacokinetics; Tetracycline

Indexed keywords

DEBUTYLHALOFANTRINE; HALOFANTRINE; TETRACYCLINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; ANTIMALARIALS; AREA UNDER CURVE; CROSS-OVER STUDIES; HALF-LIFE; HUMANS; MALE; PHENANTHRENES; TETRACYCLINE;

EID: 3142626565     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2004.02087.x     Document Type: Article

References (19)

1. Wirima J, Molyneux ME, Khoromana C, Gilles HM. Clinical trials with halofantrine hydrochloride in Malawi. Lancet 1988; ii: 250-2.
2. Bryson HM, Goa K. Halofantrine: a review of its antimalarial activity, pharmacokinetics properties and therapeutic potentials. Drugs 1992; 43: 236-58.
3. Karbwang J, Na Bangchang K. Clinical pharmacokinetics of halofantrine. Clin Pharmacokinet 1994; 27: 104-19.
4. Abernethy RD, Wesche DL, Barbey JT, Ohrt C, Mohanty S, Pezzullo JC, Schuster BG. Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation. Br J Clin Pharmacol 2001; 51: 231-7.
5. White NJ, Olliaro PL. Rationale for combination therapy for malaria. Parasitol Today 1996; 12: 399-401.
6. White NJ. Preventing antimalarial drug resistance through combinations. Drug Resistance Updates 1998; 1: 3-9.
7. Gomes M, Pang L. Interventions to improve antimalarials use. Bull WHO 1998; 76: 43-57.
8. Karbwang J, Molunto P, Bunnag D, Harinasuta T. Plasma quinine in patient with Falciparum malaria when given alone or in combination with tetracycline with or without primaquine. SE Asian J Trop Med Public Health 1991; 22: 72-76.
9. Karbwang J, Na Bangchang K, Back DJ, Bunnag D, Rooney W. Effect of tetracycline on mefloquine pharmacokinetics in Thai males. Eur J Chin Pharmacol 1992; 43: 567.
10. Gustaffson LL, Beerman B, Abdi YA. Handbook of Drugs for Tropical Parasitic Infections. Taylor & Francis, London 1987.
11. Zhao X, Ishizaki T. Metabolic interactions of selected antimalarial and non-antimalarial drugs with the major pathway (3-hydroxylation) of quinine in human liver microsomes. Br J Clin Pharmacol 1997; 44: 505-11.
12. Halliday RC, Jones BC, Smith DA, Kitteringham NR, Park BK. An investigation of the interaction between halofantrine, CYP2D6 and CYP3A4: studies with human liver microsomes and heterologous enzyme expression systems. Br J Clin Pharmacol 1995; 40: 369-79.
13. Basco LK, Gillotin C, Gimenez F, Farinotti R, Le-Bras J. Antimalarial activity in vitro of the N-desbutyl derivative of halofantrine. Trans R Soc Trop Med Hyg 1992; 86: 12-3.
14. Onyeji CO, Aideloje SO. Ion-pair reversed-phase high-performance liquid chromatographic analysis of halofantrine and desbutylhalofantrine in human plasma. Ther Drug Monit 1997; 19: 682-7.
15. Gibaldi M, Perrier D. Pharmacokinetics, 2nd edn. Marcel Dekker, New York 1982.
16. Milton KA, Edwards G, Ward SA, Orme M, Breckenridge AM. Pharmacokinetics of halofantrine in man: Effect of food and dose size. Br J Clin Pharmacol 1989; 28: 71-7.
17. Aideloje SO, Onyeji Ugwu NC. Altered pharmacokinetics of halofantrine by an antacid, magnesium carbonate. Eur J Pharm Biopharm 1998; 46: 299-303.
18. Schwartz DE, Eckert G, Hartmann D, Webster B, Richard-Lenoble D, Ekue JM, Bertillini. Single dose kinetics of mefloquine in man. Chemother 1982; 28: 70-84.
19. Baune B, Furlan V, Taburet AM, Farinotti R. Effects of selected antimalarial drugs and inhibitors of Cytochrome - 450 3A4 on halofantrine metabolism by human liver microsomes. J Pharmacol Exp Ther 1997; 5: 565-8.